The real world value of medicines

• • Collaboration
  • Hot Topics

  See all topics

  Cardiovascular Infectious Disease Neuroscience Oncology Respiratory Collaboration Hot Topics

  

  Today I’m at the Financial Times Global Pharmaceutical and Biotechnology Conference 2012 for a discussion on real world evidence (RWE). It’s a great opportunity to debate how RWE can best help healthcare systems understand and value the role of medicines in delivering better outcomes for patients and important efficiencies for healthcare systems.

  To me, RWE delivers benefits in three key ways:

  • It informs drug development strategies so that they are more clearly aligned to healthcare needs
  • It reduces uncertainty in predicting the use/outcomes and costs of introducing new health technologies
  • It is increasingly enabling a learning healthcare environment where quality and efficiencies can be more easily assessed and new pricing and incentive models are made possible

  I have no doubt that the potential of RWE can only be realised through collaboration – many parties working together to create a more evidenced-based, complete pictures of the patient experience. Just today AstraZeneca announced a memorandum of understanding with the Health and Social Care Information Centre (HSCIC) to improve the usefulness of real-world data in healthcare decision making and better understand the role medicines play in helping patients with chronic diseases in England.

  View the press release here. 

  Together AstraZeneca and the HSCIC will develop important capabilities for linking disparate sources of real-world health information from the National Health Service for healthcare decision-making and business intelligence purposes, while adhering to strict information governance principles ensuring patient confidentiality. This collaboration is the first of its kind between a pharmaceutical company and the HSCIC, England’s central, authoritative source of health and social care information, and will support the wider U.K. Government Life Sciences strategy and Growth Agenda.

  Another collaboration we have is with Healthcore, the health outcomes research subsidiary of WellPoint, Inc. Marcus Wilson, the president and co-founder of HealthCore is on the panel with me at the FT Conference, and you can hear more insights from him here.

  If you want to learn more about RWE, check out this new feature on our website.

  Tags

  Conferences partnership Payer Real World Evidence
  • Previous article Continuing our research in Tuberculosis
  • Next article The progression of AZD5847
  Back

  • share
  • 
  • 
  • 
  • 

• Leave a Comment Cancel reply

  

  Login to comment

• Pingback: Sustainable healthcare: the value of innovative medicines | LabTalk - the AstraZeneca science blog

• © AstraZeneca 2013
• Comment policy
• Legal information
• Privacy statement
• AstraZeneca.com

Login

or

• Email address
  
• Password
  
• Forgotten your password?
• I have read and accept the Comment policy

• Dont have an account? Register now

Thanks for your registration

We have sent you an email with
your login details

To add a photo or job title to your comments visit the
Edit your account page

Continue

Thanks for your comment

We review all comments before
publishing.

For more information read the Comment policy

To add or edit your profile photo visit the
Edit your account page

Thank you

The changes to your account have
now been saved.

Deleting your account?

Are you sure you want to delete
your LabTalk account?

Cancel Delete account

Register

or

• Log in | Forgot Password?

Reset Password

• Username or E-mail:
  

Log in | Register

Our site uses cookies. Find out what cookies are and why we use them. If you continue to use our site you consent to us using cookies in this way.